Interstitial Lung Disease in Systemic Sclerosis: Diagnosis and ManagementMary Beth Scholand1*, Elisabeth Carr1, Tracy Frech2, Nathan Hatton1, Boaz Markewitz1 and Allen Sawitzke2
- *Corresponding Author:
- Mary Beth Scholand
Division of Pulmonary
Department of Internal Medicine
University Hospital Pulmonary
Salt Lake City, UT 84132, USA
E-mail: [email protected]
Received date: December 02, 2011; Accepted date: February 16, 2012; Published date: February 18, 2012
Citation: Scholand MB, Carr E, Frech T, Hatton N, Markewitz B, et al. (2012) Interstitial Lung Disease in Systemic Sclerosis: Diagnosis and Management. Rheumatology S1:008. doi: 10.4172/2161-1149.S1-008
Copyright: © 2012 Scholand MB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In 460 B.C., Hippocrates described a syndrome of thickened skin. It wasn’t until 1752 that this condition was described in more detail by Carlo Curzio. The term “scleroderma” was first used by Giovambattista Fantonetti in 1836. There was little interest in this disease again until the mid-late 1900’s and now it is a clearly defined disease with ongoing research into pathophysiology and treatment options. Scleroderma is broken down into three main categories: localized, systemic and sine. The first, localized sclerosis is limited to the skin. It has deep and extensive involvement of the skin but spares any internal organ involvement. Systemic Scleroderma (SSc) is divided into limited and diffuse based on the extent of skin involvement. Limited cutaneous (lcSSc) can involve the forearms, hands, legs, feet and face. Diffuse cutaneous (dcSSc) can involve any body area. Both will involve internal organs, differentiating them from the localized form. The last major category, Sine (ssSSc), is rare and involves only internal organs, sparing the skin.